{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:28:31Z","timestamp":1788344911857,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/mt.2016.92","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T07:21:55Z","timestamp":1462778515000},"page":"1302-1311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy"],"prefix":"10.1016","volume":"24","author":[{"given":"Olivier","family":"Bornert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"K\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"van den Akker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna MG","family":"Pasmooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2016.92_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.det.2009.10.020","article-title":"Dystrophic epidermolysis bullosa: pathogenesis and clinical features","volume":"28","author":"Bruckner-Tuderman","year":"2010","journal-title":"Dermatol Clin"},{"key":"10.1038\/mt.2016.92_bib2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/0008-5472.CAN-15-1348","article-title":"Injury-driven stiffening of the dermis expedites skin carcinoma progression","volume":"76","author":"Mittapalli","year":"2016","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.92_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12703\/P6-35","article-title":"Advances in understanding and treating dystrophic epidermolysis bullosa","volume":"6","author":"Vanden Oever","year":"2014","journal-title":"F1000Prime Rep"},{"key":"10.1038\/mt.2016.92_bib4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/sj.jid.5700117","article-title":"Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa","volume":"126","author":"Goto","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mt.2016.92_bib5","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","article-title":"Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients","volume":"126","author":"Goto","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mt.2016.92_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/jid.2010.356","article-title":"Overcoming obstacles for gene therapy for recessive dystrophic epidermolysis bullosa","volume":"131","author":"Lanuti","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mt.2016.92_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/mt.2014.14","article-title":"Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy","volume":"22","author":"Sallach","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.92_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"10.1038\/mt.2016.92_bib9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1038\/mt.2016.92_bib10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1006\/geno.1993.1225","article-title":"Exon structure of the human dystrophin gene","volume":"16","author":"Roberts","year":"1993","journal-title":"Genomics"},{"key":"10.1038\/mt.2016.92_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/humu.1380040102","article-title":"Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations","volume":"4","author":"Roberts","year":"1994","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2016.92_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1038\/mt.2016.92_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1038\/mt.2016.92_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1038\/mt.2016.92_bib15","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1038\/mtna.2014.6","article-title":"What can we learn from clinical trials of exon skipping for DMD?","volume":"3","author":"Lu","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1038\/mt.2016.92_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1346-8138.2010.01008.x","article-title":"Exon 87 skipping of the COL7A1 gene in dominant dystrophic epidermolysis bullosa","volume":"38","author":"Koga","year":"2011","journal-title":"J Dermatol"},{"key":"10.1038\/mt.2016.92_bib17","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1111\/j.1365-2230.2009.03254.x","article-title":"A novel de novo splice-site mutation in the COL7A1 gene in dominant dystrophic epidermolysis bullosa (DDEB): specific exon skipping could be a prognostic factor for DDEB pruriginosa","volume":"34","author":"Saito","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1038\/mt.2016.92_bib18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1523-1747.1999.00709.x","article-title":"Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations","volume":"113","author":"McGrath","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mt.2016.92_bib19","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/bjd.13945","article-title":"A COL7A1 variant leading to in-frame skipping of exon 15 attenuates disease severity in recessive dystrophic epidermolysis bullosa","volume":"173","author":"Schwieger-Briel","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1038\/mt.2016.92_bib20","doi-asserted-by":"crossref","first-page":"e0145620","DOI":"10.1371\/journal.pone.0145620","article-title":"Deletion of dystrophin in-frame exon 5 leads to a severe phenotype: guidance for exon skipping strategies","volume":"11","author":"Toh","year":"2016","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.92_bib21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/hum.2014.086","article-title":"Translational and regulatory challenges for exon skipping therapies","volume":"25","author":"Aartsma-Rus","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2016.92_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/geno.1994.1239","article-title":"Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene","volume":"21","author":"Christiano","year":"1994","journal-title":"Genomics"},{"key":"10.1038\/mt.2016.92_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1083\/jcb.138.3.719","article-title":"Laminin 5 binds the NC-1 domain of type VII collagen","volume":"138","author":"Rousselle","year":"1997","journal-title":"J Cell Biol"},{"key":"10.1038\/mt.2016.92_bib24","doi-asserted-by":"crossref","first-page":"14516","DOI":"10.1074\/jbc.272.23.14516","article-title":"Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal-dermal adherence in human skin","volume":"272","author":"Chen","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.92_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1523-1747.1999.00491.x","article-title":"NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats","volume":"112","author":"Chen","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mt.2016.92_bib26","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.bbrc.2006.03.034","article-title":"High-affinity binding of the NC1 domain of collagen VII to laminin 5 and collagen IV","volume":"343","author":"Brittingham","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2016.92_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1083\/jcb.131.2.551","article-title":"Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain","volume":"131","author":"Bruckner-Tuderman","year":"1995","journal-title":"J Cell Biol"},{"key":"10.1038\/mt.2016.92_bib28","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/humu.21551","article-title":"The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations","volume":"32","author":"van den Akker","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2016.92_bib29","doi-asserted-by":"crossref","first-page":"9042","DOI":"10.1016\/S0021-9258(19)84485-X","article-title":"Large complex globular domains of type VII procollagen contribute to the structure of anchoring fibrils","volume":"261","author":"Lunstrum","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.92_bib30","doi-asserted-by":"crossref","first-page":"19228","DOI":"10.1074\/jbc.273.30.19228","article-title":"Some, but not all, glycine substitution mutations in COL7A1 result in intracellular accumulation of collagen VII, loss of anchoring fibrils, and skin blistering","volume":"273","author":"Hammami-Hauasli","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.92_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/bj2880131","article-title":"Characterization of three osteogenesis imperfecta collagen alpha 1(I) glycine to serine mutations demonstrating a position-dependent gradient of phenotypic severity","volume":"288 (Pt 1)","author":"Bateman","year":"1992","journal-title":"Biochem J"},{"key":"10.1038\/mt.2016.92_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tig.2003.11.004","article-title":"Collagens, modifying enzymes and their mutations in humans, flies and worms","volume":"20","author":"Myllyharju","year":"2004","journal-title":"Trends Genet"},{"key":"10.1038\/mt.2016.92_bib33","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","article-title":"Preclinical PK and PD studies on 2\u2019-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model","volume":"18","author":"Heemskerk","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.92_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/978-1-62703-227-8_29","article-title":"Cell- and protein-based therapy approaches for epidermolysis bullosa","volume":"961","author":"Nystr\u00f6m","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mt.2016.92_bib35","doi-asserted-by":"crossref","first-page":"30248","DOI":"10.1074\/jbc.M109.045294","article-title":"Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII","volume":"284","author":"Fritsch","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.92_bib36","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/mt.2015.58","article-title":"High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa","volume":"23","author":"K\u00fchl","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.92_bib37","doi-asserted-by":"crossref","first-page":"e64243","DOI":"10.1371\/journal.pone.0064243","article-title":"Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect","volume":"8","author":"Nystr\u00f6m","year":"2013","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.92_bib38","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1089\/10430340260201743","article-title":"A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line","volume":"13","author":"Mecklenbeck","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2016.92_bib39","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1074\/jbc.M108779200","article-title":"The recombinant expression of full-length type VII collagen and characterization of molecular mechanisms underlying dystrophic epidermolysis bullosa","volume":"277","author":"Chen","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.92_bib40","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1172\/JCI68127","article-title":"Collagen VII plays a dual role in wound healing","volume":"123","author":"Nystr\u00f6m","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2016.92_bib41","doi-asserted-by":"crossref","first-page":"17838","DOI":"10.1074\/jbc.M709452200","article-title":"Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis","volume":"283","author":"Woodley","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.92_bib42","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI34292","article-title":"A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy","volume":"118","author":"Fritsch","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2016.92_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.92_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/nat.2013.0461","article-title":"Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases","volume":"24","author":"Siva","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"10.1038\/mt.2016.92_bib45","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jid.2016.02.002","article-title":"Collagen VII half-life at the dermal-epidermal junction zone: implications for mechanisms and therapy of genodermatoses","volume":"136","author":"K\u00fchl","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mt.2016.92_bib46","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1073\/pnas.95.9.4929","article-title":"Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs","volume":"95","author":"Gorman","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2016.92_bib47","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/hmg\/8.13.2415","article-title":"Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations","volume":"8","author":"Suter","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2016.92_bib48","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/mt.2014.151","article-title":"Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients","volume":"22","author":"Le Guiner","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.92_bib49","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/gt.2010.36","article-title":"Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa","volume":"17","author":"Pendaries","year":"2010","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2016.92_bib50","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/jid.2014.118","article-title":"Mechanisms of natural gene therapy in dystrophic epidermolysis bullosa","volume":"134","author":"Kiritsi","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mt.2016.92_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-61779-767-5_8","article-title":"Overview on AON design","volume":"867","author":"Aartsma-Rus","year":"2012","journal-title":"Methods Mol Biol"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616303628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616303628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:50:16Z","timestamp":1761501016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616303628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1525001616303628"],"URL":"https:\/\/doi.org\/10.1038\/mt.2016.92","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mt.2016.92","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}